Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Intranasal Gam-COVID-Vac (SPRAY)
NCT05248373Phase 2Unknown
- Start
- Mar 2022
- Primary completion
- Feb 2023
- Modality
- Viral Vector Vaccines
01
Overview
A Phase 2 trial of Gam-COVID-Vac in coronavirus disease 2019 (COVID-19). Status: unknown.
02
Drugs
Gam-COVID-Vac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05248373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05248373.